Residency · Residency · Family Medicine

Chronic Pain Management: A Multimodal Approach

Overview

Chronic pain, defined as pain persisting beyond three months, affects approximately 50 million US adults and is the most common reason for seeking medical care. It is no longer understood as merely a prolonged version of acute pain but as a disease state in its own right, involving neuroplastic changes in the central nervous system that perpetuate pain signaling well beyond the resolution of any initial injury. A biopsychosocial framework and multimodal management strategy that prioritizes non-pharmacologic and non-opioid therapies is essential for the family physician.

Pain Pathophysiology

Chronic pain falls into three broad mechanistic categories, each with distinct treatment implications. Nociceptive pain results from activation of peripheral nociceptors by ongoing tissue injury and can be somatic (musculoskeletal) or visceral. Neuropathic pain arises from damage or dysfunction of the somatosensory nervous system and is characterized by burning, shooting, and tingling sensations. Nociplastic pain, the most recently defined category, involves altered nociceptive processing within the central nervous system without clear evidence of tissue or nerve damage. Fibromyalgia, chronic widespread pain, and irritable bowel syndrome are classic examples. Central sensitization, in which the CNS amplifies neural signaling to produce pain hypersensitivity, is a unifying mechanism across many chronic pain conditions. Identifying the predominant pain type guides targeted treatment selection.

Biopsychosocial Assessment

Comprehensive Pain Evaluation

A thorough evaluation includes pain location, quality, intensity (using a 0-to-10 numeric rating scale or visual analog scale), duration, and aggravating and alleviating factors. Functional assessment is critical: the impact on work, activities of daily living, sleep, relationships, and mood. The PEG scale (Pain, Enjoyment, General Activity) provides a brief, validated functional assessment tool. A detailed history of prior treatments and their responses helps avoid repeating ineffective approaches.

Psychosocial Factors

Depression (screened with PHQ-9), anxiety (GAD-7), PTSD, and pain catastrophizing (Pain Catastrophizing Scale) should all be assessed, as they significantly influence both pain experience and treatment response. Adverse childhood experiences correlate strongly with chronic pain in adulthood. Social determinants including employment status, financial stress, social support, and substance use history provide important context. Fear-avoidance beliefs and kinesiophobia (fear of movement) are among the strongest predictors of disability. "Yellow flags" for chronicity include the belief that pain always signals harm, passive coping strategies, prolonged rest, and social withdrawal.

Non-Pharmacologic Therapies (First-Line)

Physical Approaches

Exercise therapy has the strongest evidence base for chronic low back pain, osteoarthritis, and fibromyalgia, combining aerobic, resistance, and flexibility components. Physical therapy offers manual therapy, therapeutic exercise, and modalities such as TENS and therapeutic ultrasound. Yoga and tai chi have moderate evidence for chronic low back pain, fibromyalgia, and osteoarthritis. Acupuncture shows moderate benefit for chronic low back pain, knee osteoarthritis, and headache with minimal risk. Massage provides short-term benefit for musculoskeletal pain. Heat and cold therapy, though simple, offer accessible adjunctive benefit.

Psychological Approaches

Cognitive behavioral therapy has the strongest evidence among psychological treatments, with a number needed to treat of approximately 2 to 4 for meaningful improvement in function and mood. It specifically targets pain catastrophizing and promotes active coping strategies. Acceptance and commitment therapy teaches psychological flexibility around pain rather than attempting to eliminate it. Mindfulness-based stress reduction reduces pain interference and improves quality of life. Pain neuroscience education, which helps patients reframe their understanding of pain mechanisms, reduces fear-avoidance behavior. Biofeedback is effective for chronic headache and temporomandibular disorders.

Interventional Approaches

Trigger point injections, epidural steroid injections (which provide short-term radiculopathy relief but limited long-term benefit), facet joint injections with medial branch blocks or radiofrequency ablation, peripheral nerve blocks, and spinal cord stimulation (for refractory neuropathic pain and failed back surgery syndrome) all have roles in selected patients. Referral to pain medicine is appropriate when first-line approaches fail.

Non-Opioid Pharmacotherapy

First-Line Options by Pain Type

Nociceptive/Musculoskeletal Pain

Acetaminophen is a safe first-line option, with a maximum dose of 3 grams per day (2 grams in patients with hepatic disease or significant alcohol use). NSAIDs (ibuprofen, naproxen, meloxicam) are often more effective but should be used at the lowest effective dose for the shortest duration due to gastrointestinal, renal, and cardiovascular risks. Topical diclofenac gel provides local effect with minimal systemic absorption and is effective for knee osteoarthritis. Celecoxib offers lower gastrointestinal risk but comparable cardiovascular risk and should be considered with a PPI for patients at high GI risk. Duloxetine, at 30 to 60 mg daily, is FDA-approved for chronic musculoskeletal pain, osteoarthritis, and fibromyalgia.

Neuropathic Pain

Gabapentin (300 to 3600 mg/day in divided doses, started low and titrated slowly) and pregabalin (150 to 600 mg/day) are first-line, though sedation, dizziness, and edema can be limiting. Pregabalin is Schedule V due to abuse potential. Duloxetine at 60 to 120 mg daily is first-line for diabetic neuropathy. Tricyclic antidepressants (amitriptyline, nortriptyline) at 10 to 150 mg at bedtime have an NNT of approximately 3 for neuropathic pain but are limited in the elderly by anticholinergic effects. Topical lidocaine 5% patches are useful for localized neuropathic pain and postherpetic neuralgia. Topical capsaicin 8% patches, applied in-clinic, deplete substance P and are effective for postherpetic neuralgia.

Nociplastic/Central Sensitization Pain (Fibromyalgia)

Fibromyalgia responds best to a combination approach. Duloxetine 60 mg daily and pregabalin 150 to 450 mg/day are both FDA-approved. Milnacipran at 50 to 100 mg twice daily is FDA-approved specifically for fibromyalgia. Amitriptyline at 10 to 50 mg at bedtime is effective off-label. Exercise is the most effective non-pharmacologic intervention for fibromyalgia. Opioids are generally ineffective and not recommended for this condition.

Other Adjunctive Agents

Muscle relaxants (cyclobenzaprine, tizanidine, baclofen) should be limited to short-term use for acute musculoskeletal spasm, as they are sedating and inappropriate for chronic use. Topiramate is used for chronic migraine prevention. Low-dose naltrexone (1.5 to 4.5 mg daily) has emerging evidence for fibromyalgia and other chronic pain conditions through an anti-inflammatory mechanism.

Opioid Therapy: When Indicated

CDC 2022 Clinical Practice Guideline (Updated)

The updated CDC guideline emphasizes that non-opioid therapies are preferred for chronic pain. Opioids should be considered only when benefits for both pain and function are expected to outweigh the risks. Importantly, the 2022 update removed rigid dose thresholds and mandatory taper requirements that were present in the 2016 guideline, as these had been causing patient harm. Before starting opioids, clear functional goals should be established, risk should be assessed, and informed consent obtained.

Risk Assessment Before Initiating

The Prescription Drug Monitoring Program should be checked before every new opioid prescription. Baseline and periodic urine drug testing confirms adherence and detects undisclosed substances. Risk assessment tools such as the Opioid Risk Tool or DIRE score help stratify misuse risk. Key risk factors include personal or family history of substance use, mental health disorders, younger age, and history of sexual abuse.

If Opioids Are Prescribed

Treatment should start with the lowest effective dose of an immediate-release opioid. Concurrent benzodiazepines should be avoided because they increase overdose risk more than ten-fold. Reassessment should occur within one to four weeks, continuing opioids only if there is meaningful improvement in both pain and function. Morphine milligram equivalents help monitor total opioid burden. Naloxone should be co-prescribed for all patients on opioids, particularly those on 50 MME per day or above, those taking concurrent benzodiazepines, or those with a history of overdose. Methadone should be avoided for pain management in primary care due to its complex pharmacokinetics.

Opioid Tapering

Tapering should be considered when there is no meaningful functional improvement, when side effects are problematic, at the patient's request, when aberrant behaviors are observed, or when doses reach 90 MME or above. A gradual taper of 10% per month is preferred for long-term use. The CDC 2022 guideline explicitly warns against abrupt discontinuation or forced rapid tapers, which cause withdrawal, uncontrolled pain, illicit drug use, and suicide. Multidisciplinary support during tapering, including behavioral health, physical therapy, and pain psychology, is essential.

Opioid Use Disorder (OUD) Recognition

OUD should be suspected when patients make early refill requests, report lost prescriptions, seek multiple prescribers, demonstrate dose escalation without functional benefit, or show functional decline. DSM-5 requires two or more of 11 criteria over 12 months for diagnosis. Since the elimination of the X-waiver requirement in 2023, any DEA-registered physician can initiate buprenorphine/naloxone treatment. Complex cases should be referred to addiction medicine.

Chronic Pain in Special Populations

In elderly patients, NSAIDs (due to renal, GI, and cardiovascular risk), tricyclic antidepressants (anticholinergic burden), and opioids (falls, constipation, cognitive impairment) should all be avoided when possible. Acetaminophen, topical agents, duloxetine, and non-pharmacologic therapies are preferred. In pregnancy, acetaminophen is the preferred analgesic, NSAIDs should be avoided in the third trimester, and opioid use should be minimized. In patients with a substance use history, non-opioid and non-addictive strategies should be maximized. If opioids are necessary, structured monitoring is essential, and buprenorphine may serve dual purposes for both pain and OUD prevention.

<image>A multimodal pain management pyramid showing the recommended hierarchy of interventions. At the base: lifestyle modifications and self-management (exercise, sleep hygiene, stress reduction). Second tier: non-pharmacologic therapies (PT, CBT, acupuncture). Third tier: non-opioid pharmacotherapy (acetaminophen, NSAIDs, SNRIs, gabapentinoids). Fourth tier: interventional procedures. At the apex: opioid therapy with structured monitoring. Show that all tiers can be used simultaneously.</image>

<image>A clinical decision flowchart for selecting non-opioid medications based on pain type: nociceptive pathway leading to NSAIDs and acetaminophen, neuropathic pathway leading to gabapentinoids and duloxetine and TCAs, and nociplastic pathway leading to duloxetine and pregabalin and exercise prescription. Include starting doses and key monitoring parameters for each medication.</image>

<image>An infographic summarizing the CDC 2022 opioid prescribing guideline key points: (1) risk-benefit assessment before starting, (2) PDMP check and baseline UDT, (3) start lowest dose IR opioid, (4) reassess in 1-4 weeks for pain AND function improvement, (5) naloxone co-prescribing, (6) avoid concurrent benzodiazepines, (7) no involuntary rapid tapers, (8) tapering protocol of 10% per month. Show these as a circular process with patient-centered shared decision-making at the center.</image>

Clinical Pearls

Chronic pain is a disease state, not just a persistent symptom. Central sensitization and neuroplastic changes perpetuate pain signaling beyond the resolution of any initial injury. Function should always be assessed alongside pain intensity, because the goal of treatment is improved function, not elimination of pain. Topical diclofenac gel is dramatically underutilized for knee osteoarthritis despite providing meaningful relief with minimal systemic risk. Gabapentin and pregabalin have abuse potential and should be prescribed with appropriate awareness. The 2022 CDC guideline removed rigid MME thresholds and explicitly warned against forced tapers, which were causing patient harm through withdrawal, uncontrolled pain, and suicide. Naloxone should be co-prescribed for any patient on opioids, with family members instructed on its use. CBT for chronic pain has an NNT of approximately 2 to 4 for meaningful functional improvement. Fibromyalgia responds best to exercise, SNRIs, pregabalin, and CBT; opioids are generally ineffective for this condition.

References

• Dowell D et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain. MMWR. 2022
• Chou R et al. Systemic Pharmacologic Therapies for Low Back Pain: ACP Guidelines. Ann Intern Med. 2017
• Finnerup NB et al. Pharmacotherapy for Neuropathic Pain: IASP NeuPSIG Guidelines. Lancet Neurol. 2015
• Clauw DJ. Fibromyalgia: A Clinical Review. JAMA. 2014
• Busse JW et al. Opioids for Chronic Noncancer Pain: BMJ Guidelines. BMJ. 2017
• AAFP Chronic Pain Management Toolkit. 2023

Read this lecture as Markdown